Philippines starts Avigan clinical trials Monday | Inquirer News

Philippines starts Avigan clinical trials Monday

/ 03:15 PM August 17, 2020

MANILA, Philippines — Clinical trials for Japan’s antiviral drug Avigan on COVID-19 patients in the Philippines will start on Monday, according to the Department of Health (DOH).

Health Undersecretary Maria Rosario Vergeire said the Avigan tablets would be given to 100 patients coronavirus patients in the country for nine months.

“Maguumpisa tayo ngayon then after 9 months magsubmit ng resulta,” Vergeire told reporters in an online media forum. (We will begin today then after nine months we will submit the result.)

Article continues after this advertisement

The trials will start in four hospitals, namely, the Philippine General Hospital, Sta. Ana Hospital, Dr. Jose M. Rodriguez Memorial Hospital, and Quirino Memorial Medical Center.

FEATURED STORIES

The government has set aside at least P18 million for the Avigan trials.

Avigan reportedly yielded positive results in treating COVID-19 patients in China, especially those with mild symptoms. [ac]

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link.

TAGS: Avigan, COVID-19, DoH, Japan, Philippines, vaccine

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.